Boston, MA 07/02/2014 (wallstreetpr) – Vape Holdings Inc (OTCMKTS:VAPE) appears to be moving in the right direction if the recent developments are anything to consider. The rampant hype in the marijuana industry has helped push the company to impressive heights, especially in early March during which the stock traded around $41.25 per share. However, the stock has also undergone devastating corrections in that it presently trades around $3 per share.
Nonetheless, the company looks financially well-placed than most other pennystocks. As a matter of fact, investors are not prepared to give up on the stock because of its impressive prospects in the emerging marijuana industry.
It is however important for investors to take note of the fact that the company could plunge deeper into more dilutions because of its convertible notes recently issued at heavy discounts. On that note, the company needs to increase its revenue so that it offsets the impact of the eminent dilution.
Neutra Corp (OTCMKTS:NTRR), a healthy lifestyle company with interest in marijuana, is expected to launch a cutting-edge delivery system that is suitable for medical marijuana application. The product is planned for launch later this month, and it will be one of a kind, which positions NTRR in good revenue standing. The lightweight, smokeless and portable tool is suitable for the delivery of substances such as dry herbs, waxes and oils.
The market value potential for the ancillary product is said to be in the region of hundreds of millions or even more. On the other hand, analysts expect the market value of cannabis horticultural equipment to be in the neighborhood of $2.57 billion this year, compared with $1.53 billion in the past year.
With New York having joined the growing list of states that have legalized medical marijuana, Neutra Corp (OTCMKTS:NTRR) looks poised to benefit from its cannabis delivery product.
Santhera Pharm Hldg (OTCMKTS:SPHDF), a Swiss drug company that has not seen profits since its IPO in 2006, is excited about the prospects of its recently approved treatment that include a rare muscular disease. The company reported that several potential sellers in the U.S. have made contact for the distribution of the drug in North America. The drug is expected to fetch about $670 million in annual sales in Europe and North America.
